Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
- 4 December 2008
- journal article
- letter
- Published by Springer Science and Business Media LLC in Cancer Immunology, Immunotherapy
- Vol. 58 (8), 1351-1353
- https://doi.org/10.1007/s00262-008-0627-x
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Review: Anti–CTLA-4 Antibody Ipilimumab: Case Studies of Clinical Response and Immune-Related Adverse EventsThe Oncologist, 2007
- CTLA-4 Blockade: Autoimmunity As TreatmentJournal of Clinical Oncology, 2005
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005
- Intravenous immunoglobulins in autoimmune- or parvovirus B19-mediated pure red-cell aplasiaAutoimmunity Reviews, 2005
- Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple optionsNephrology Dialysis Transplantation, 2005
- New Insights into the Pathophysiology of Acquired CytopeniasHematology, 2000
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996